Search

Author/Creator Ritgen, M.

1. BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG). (June 2017)

Authors:
Cramer, P.; von Tresckow, J.; Bahlo, J.; Robrecht, S.; Al‐Sawaf, O.; Langerbeins, P.; Engelke, A.; Fink, A.M.; Fischer, K.; Seiler, T.; von Weikersthal, L.Fischer; Hebart, H.; Kreuzer, K.A.; Ritgen, M.; Kneba, M.; Wendtner, C.M.; Stilgenbauer, S.; Eichhorst, B.; Hallek, M.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
25
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES. (12th June 2019)

Authors:
Fischer, K.; Porro Lurà, M.; Al‐Sawaf, O.; Bahlo, J.; Fink, A.; Tandon, M.; Dixon, M.; Robrecht, S.; Warburton, S.; Humphrey, K.; Samoylova, O.; Liberati, A.M.; Pinilla‐Ibarz, J.; Opat, S.; Sivcheva, L.; Le Dû, K.; Fogliatto, L.M.; Utoft Niemann, C.; Weinkove, R.; Robinson, S.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
82
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL. (12th June 2019)

Authors:
Al‐Sawaf, O.; Lilienweiss, E.; Bahlo, J.; Robrecht, S.; Fink, A.; Patz, M.; Tandon, M.; Humphrey, K.; Jiang, Y.; Schary, W.; Porro Lurà, M.; Ritgen, M.; Tausch, E.; Stilgenbauer, S.; Eichhorst, B.; Fischer, K.; Hallek, M.; Kreuzer, K.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
104
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P652: MEASURING MINIMAL RESIDUAL DISEASE BEYOND 10-4 THROUGH IGHV LEADER-BASED NEXT GENERATION SEQUENCING IMPROVES PROGNOSTIC STRATIFICATION IN CHRONIC LYMPHOCYTIC LEUKEMIA. (23rd June 2022)

Authors:
Hengeveld, P.; van der Klift, M.; Kolijn, P. M.; Davi, F.; Kavelaars, F.; de Jonge, E.; Robrecht, S.; Assmann, J.; van der Straten, L.; Ritgen, M.; Westerweel, P.; Fischer, K.; Goede, V.; Hallek, M.; Levin, M.-D.; Langerak, A.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
550
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P681: EUROFLOW STANDARDIZATION TECHNIQUE AND NORMALIZATION PROCEDURES IN LONGITUDINAL FLOW CYTOMETRIC EXPRESSION ANALYSIS OF CD20 IN CLL PATIENTS RECEIVING ANTI-CD20 DIRECTED THERAPY. (23rd June 2022)

Authors:
Walter, P. J.; Schilhabel, A.; Cramer, P.; von Tresckow, J.; Kohlscheen, S.; Fischer, K.; Eichhorst, B.; Böttcher, S.; Brüggemann, M.; Kneba, M.; Hallek, M.; Ritgen, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
577
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON-RESPONSE IN PATIENTS TREATED WITH FIXED-DURATION VENETOCLAX-OBINUTUZUMAB. (23rd June 2022)

Authors:
Al-Sawaf, O.; Jin, H. Y.; Zhang, C.; Choi, Y.; Balasubramanian, S.; Robrecht, S.; Kotak, A.; Chang, N.; Fink, A.-M.; Tausch, E.; Schneider, C.; Ritgen, M.; Kreuzer, K.-A.; Chyla, B.; Paulson, J.; Eichhorst, B.; Stilgenbauer, S.; Jiang, Y.; Hallek, M.; Fischer, K.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
44
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY. (23rd June 2022)

Authors:
Al-Sawaf, O.; Zhang, C.; Robrecht, S.; Kotak, A.; Chang, N.; Fink, A.-M.; Tausch, E.; Schneider, C.; Ritgen, M.; Kreuzer, K.-A.; Chyla, B.; Eichhorst, B.; Jiang, Y.; Stilgenbauer, S.; Hallek, M.; Fischer, K.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
49
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Skin involvement by chronic lymphocytic leukaemia is frequently associated with unrelated neoplastic or inflammatory cutaneous disease and is not indicative of general disease progression. (1st January 2019)

Authors:
Thiesen, I.; Wehkamp, U.; Brüggemann, M.; Ritgen, M.; Murga Penas, E.M.; Klapper, W.; Oschlies, I.
Journal:
British journal of dermatology
Issue:
Volume 180:Number 1(2019)
Page Start:
227
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Skin involvement by chronic lymphocytic leukaemia is frequently associated with unrelated neoplastic or inflammatory cutaneous disease and is not indicative of general disease progression. (25th October 2018)

Authors:
Thiesen, I.; Wehkamp, U.; Brüggemann, M.; Ritgen, M.; Murga Penas, E.M.; Klapper, W.; Oschlies, I.
Journal:
British journal of dermatology
Issue:
Volume 180:Number 1(2019)
Page Start:
227
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY. (17th June 2021)

Authors:
Al‐Sawaf, O.; Zhang, C.; Robrecht, S.; Tandon, M.; Panchal, A.; Fink, A.‐M.; Tausch, E.; Ritgen, M.; Kreuzer, K.‐A.; Kim, S.; Wendtner, C.; Eichhorst, B.; Stilgenbauer, S.; Jiang, Y.; Hallek, M.; Fischer, K.
Journal:
Hematological oncology
Issue:
Volume 39(2021)Supplement 2
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗